Publications

Viral hepatitis poses a substantial global health burden. The most often seen abnormalities after the diagnosis ofHepatitis B Virus (HBV) generally encompass haematological abnormalities and changes in liver parameters. Theaim of this study is to evaluate the haematological variables and liver enzymes, specifically aspartate transaminase(AST) and alanine transaminase (ALT), among blood donors who have contracted the hepatitis B virus (HBV) atthe Federal Medical Centre (FMC) in Owo. The study encompassed a cohort of 70 individuals, with the experimentalgroup comprising 50 individuals who exhibited positive results for the hepatitis B virus (HBV). The control groupconsisted of a sample of twenty (20) apparently healthy adults. The mean levels of red blood cells (RBC), hematocrit(HCT), haemoglobin (HGB), and platelets (PLT) demonstrated a statistically significant reduction in personsrelative to the control group, as evidenced by the p-values of 0.002, 0.001, 0.035, and 0.002, respectively. Nostatistically significant decrease in the average concentration of white blood cells (WBC) was reported among theparticipants in comparison to the control group (p=0.236). The study revealed a significantly increased meanconcentration of alanine aminotransferase (ALT) in the participants as compared to the control group (p=0.016).The study findings revealed that there was no statistically significant difference in the levels of AST observedbetween the participants and the control group (p = 0.285). The present study has provided evidence to support theuse of haematological parameters and liver enzymes as a reliable and accurate approach for assessing the severity ofhepatitis B virus (HBV) infection. Therefore, it is crucial to incorporate the surveillance of patients even after theirrecovery from hepatitis B virus infection as an essential element of their healthcare.Keywords: Hepatitis B, Liver, Haematological Parameter, Liver EnzymeINTRODUCTIONThe prevalence of Hepatitis B (HB) infection is amatter of great concern on a global scale, as it has thepotential to greatly impact public health [1-4]. Thehepatitis B virus (HBV) has exhibited a substantialglobal prevalence, impacting a population over twobillion individuals [5-8]. Moreover, a significantproportion of this affected population, estimated to bebetween 360 and 400 million individuals, is known tosuffer from chronic HBV infection [10-16].However, it has been determined that the anticipatedannual mortality attributable to HB infection spans arange of 0.61 million to one million [17-20].Furthermore, the